Cargando…

Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes

INTRODUCTION: Conventional care packages around screening for sexually transmitted infections (STIs) entail multiple clinic visits and precipitate losses to follow-up. To prevent these losses, multiplexed technologies for STIs (immunochromatographic tests/devices/assays and molecular assays that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Naeem, Faheel, Karellis, Angela, Nair, Suma, Routy, Jean-Pierre, Yansouni, Cédric Philippe, Kim, John, Pai, Nitika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311302/
https://www.ncbi.nlm.nih.gov/pubmed/34301675
http://dx.doi.org/10.1136/bmjgh-2021-005670
_version_ 1783728933352505344
author Naeem, Faheel
Karellis, Angela
Nair, Suma
Routy, Jean-Pierre
Yansouni, Cédric Philippe
Kim, John
Pai, Nitika
author_facet Naeem, Faheel
Karellis, Angela
Nair, Suma
Routy, Jean-Pierre
Yansouni, Cédric Philippe
Kim, John
Pai, Nitika
author_sort Naeem, Faheel
collection PubMed
description INTRODUCTION: Conventional care packages around screening for sexually transmitted infections (STIs) entail multiple clinic visits and precipitate losses to follow-up. To prevent these losses, multiplexed technologies for STIs (immunochromatographic tests/devices/assays and molecular assays that can screen multiple pathogens or multiple strains of one STI) can yield same-day results in a single visit. Research evidence of patient-centred (preference, satisfaction) and clinical health outcomes (feasibility, case positivity, uptake, impact) has not been synthesised. We conducted a systematic review to fill this gap. METHODS: For the period 2009–2020, two independent reviewers searched PubMed and Embase, retrieved 4440 citations and abstracted data from 42 relevant studies. RESULTS: Of 42 studies, 10 (23.8%) evaluated multiplexed immunochromatographic and 32 (76.2%) molecular assays. Outcomes were reported as follows: preference (n=3), satisfaction (n=2), uptake (n=1), feasibility (n=2), case positivity (n=42) and impact (n=11). Screened populations included various at-risk groups. A majority (86.1%–92.4%) of participants preferred (60.2%–97.2%) multiplexed technologies (over conventional testing). Compared with conventional lab-based testing, test uptake improved by 99.4% (hepatitis C), 99.6% (Trichomonas vaginalis), 78.6% (hepatitis B) and 42.0% (HIV). Varying case positivities were documented depending on populations screened: HIV (1.8%–29.3%), hepatitis B (1.1%–23.9%), hepatitis C (0.5%–42.2%), Chlamydia trachomatis (2.8%–30.2%), Neisseria gonorrhoeae (0.0%–30.3%) and T. vaginalis (0.0%–32.7%). Regarding impact, 70.0%–100.0% of screened participants were linked to care, with result turnaround times ranging from 14 min (immunochromatographic assays) to 300 min (molecular assays). CONCLUSIONS: Compared with conventional lab-based testing, rapid multiplexed technologies were preferred by testees and led to quicker turnaround times for many STIs yielding same-day results thereby allowing to initiate rapid linkages to care. They were further shown to be highly feasible and impactful for detection and treatment facilitation. Based on these promising results, multiplexed technologies offer potential to screen at-risk populations to reduce onward STI transmission worldwide.
format Online
Article
Text
id pubmed-8311302
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-83113022021-08-13 Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes Naeem, Faheel Karellis, Angela Nair, Suma Routy, Jean-Pierre Yansouni, Cédric Philippe Kim, John Pai, Nitika BMJ Glob Health Original Research INTRODUCTION: Conventional care packages around screening for sexually transmitted infections (STIs) entail multiple clinic visits and precipitate losses to follow-up. To prevent these losses, multiplexed technologies for STIs (immunochromatographic tests/devices/assays and molecular assays that can screen multiple pathogens or multiple strains of one STI) can yield same-day results in a single visit. Research evidence of patient-centred (preference, satisfaction) and clinical health outcomes (feasibility, case positivity, uptake, impact) has not been synthesised. We conducted a systematic review to fill this gap. METHODS: For the period 2009–2020, two independent reviewers searched PubMed and Embase, retrieved 4440 citations and abstracted data from 42 relevant studies. RESULTS: Of 42 studies, 10 (23.8%) evaluated multiplexed immunochromatographic and 32 (76.2%) molecular assays. Outcomes were reported as follows: preference (n=3), satisfaction (n=2), uptake (n=1), feasibility (n=2), case positivity (n=42) and impact (n=11). Screened populations included various at-risk groups. A majority (86.1%–92.4%) of participants preferred (60.2%–97.2%) multiplexed technologies (over conventional testing). Compared with conventional lab-based testing, test uptake improved by 99.4% (hepatitis C), 99.6% (Trichomonas vaginalis), 78.6% (hepatitis B) and 42.0% (HIV). Varying case positivities were documented depending on populations screened: HIV (1.8%–29.3%), hepatitis B (1.1%–23.9%), hepatitis C (0.5%–42.2%), Chlamydia trachomatis (2.8%–30.2%), Neisseria gonorrhoeae (0.0%–30.3%) and T. vaginalis (0.0%–32.7%). Regarding impact, 70.0%–100.0% of screened participants were linked to care, with result turnaround times ranging from 14 min (immunochromatographic assays) to 300 min (molecular assays). CONCLUSIONS: Compared with conventional lab-based testing, rapid multiplexed technologies were preferred by testees and led to quicker turnaround times for many STIs yielding same-day results thereby allowing to initiate rapid linkages to care. They were further shown to be highly feasible and impactful for detection and treatment facilitation. Based on these promising results, multiplexed technologies offer potential to screen at-risk populations to reduce onward STI transmission worldwide. BMJ Publishing Group 2021-07-23 /pmc/articles/PMC8311302/ /pubmed/34301675 http://dx.doi.org/10.1136/bmjgh-2021-005670 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Naeem, Faheel
Karellis, Angela
Nair, Suma
Routy, Jean-Pierre
Yansouni, Cédric Philippe
Kim, John
Pai, Nitika
Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title_full Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title_fullStr Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title_full_unstemmed Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title_short Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
title_sort multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311302/
https://www.ncbi.nlm.nih.gov/pubmed/34301675
http://dx.doi.org/10.1136/bmjgh-2021-005670
work_keys_str_mv AT naeemfaheel multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT karellisangela multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT nairsuma multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT routyjeanpierre multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT yansounicedricphilippe multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT kimjohn multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes
AT painitika multiplexedtechnologiesforsexuallytransmittedinfectionsglobalevidenceonpatientcenteredandclinicalhealthoutcomes